Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation ...

Linda Nolan has spent two years sharing every twist and turn of her cancer journey in her Daily Mirror column, Straight From ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.